House Bill Targets Looming $20 Billion Tax On MedTech Industry
Wednesday, April 10, 2019 02:46 PM

April 10, 2019. WASHINGTON, D.C. – Scott Whitaker, president and CEO of the Advanced Medical Technology Association (AdvaMed), issued the following statement on introduction of bipartisan legislation (H.R. 2207) in the U.S. House of Representatives to permanently repeal the medical device excise tax:

“America’s medical technology industry is facing a $20 billion tax increase at year-end, when the current medical device tax suspension expires. Urgent action is essential to protect future medtech innovations that benefit patients and to avoid putting good-paying U.S. jobs at risk. 

“House introduction today of the Protect Medical Innovation Act in the 116thCongress brings us one step closer to ensuring this innovation-stifling burden on the medtech industry never returns, supporting continued American leadership of this vital industry. 

Georgia Bio Names Westminster School Junior as Georgia BioGENEius Winner
Wednesday, April 10, 2019 08:52 AM

Ananya Ganesh Advances to Philadelphia in International Competition Against Top Students 

Atlanta, GA (April 10, 2019)– Georgia Bio and the Georgia BioEd Institute today named Ananya Ganesh, a junior at The Westminster Schools in Atlanta, GA, as the winner of the 2019 Georgia BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research and innovation in the biotechnology field.  As Georgia’s BioGENEius finalist, Ananya will attend the 2019 BIO International Convention, the industry’s trade conference from June 3-6 in Philadelphia, PA where she will engage with leading companies, scientists and innovators currently transforming the scientific landscape in order to gain valuable insights into an industry making significant contributions to the world.

While in Philadelphia, Ananya will compete against high school students from the U.S., Canada and Germany in the International BioGENEius Challenge. The student projects will represent a range of biotechnology topics such as healthcare, agriculture, and the environment.

FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
Tuesday, April 09, 2019 12:00 AM
One in Two Women in the United States Will Suffer a Fracture in Her Lifetime Due to Osteoporosis(1)
EVENITY is the First and Only Bone Builder With a Dual Effect That Both Increases Bone Formation and Decreases Bone Loss(2)
EVENITY Rapidly Reduces Fracture Risk and Builds New Bone With 12 Months of Therapy(2)


THOUSAND OAKS, Calif. and BRUSSELS, April 9, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY is the first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (or bone loss) to rapidly reduce the risk of fracture. A full course of EVENITY therapy is 12 monthly doses administered by a healthcare provider.2 Since osteoporosis is a chronic disease, continued therapy with an anti-resorptive agent should be considered once EVENITY therapy is completed.

Experience the interactive Multichannel News Release here:

Alpharetta biopharma company names board member as interim CEO
Monday, April 08, 2019 02:35 PM

An Alpharetta company that is working on treatments for eye disease patients has named a member of its board of directors as interim CEO.

George Lasezkay succeeds Daniel H. White as chief executive of Clearside Biomedical Inc. (NASDAQ: CLSD). White resigned as president, CEO and as a member of the Clearside board to pursue other opportunities, according to a company announcement.

Lasezkay has served as an independent director on the boards of a number of domestic and foreign emerging biopharmaceutical companies for the past 15 years. He has been a director of Clearside since August 2017.  Previously, he served as executive vice president and general counsel at Acucela Inc., a development stage company that identifies and develops ophthalmic therapeutics. For the 10 years prior to Acucela, he was president of Horizon Pharma Group, a private life sciences consultancy practice. Prior to Horizon, Lasezkay was corporate vice president for corporate development at Allergan Inc.

Congressman Collins Honored as Innovator in Biotechnology
Thursday, April 04, 2019 12:00 AM

Washington, D.C. (April 4, 2019) – Congressman Doug Collins was recognized today by the Biotechnology Innovation Organization (BIO) for his leadership as an Innovator in Biotechnology. Congressman Collins received the award in conjunction with today’s BIO Legislative Day Fly-In.

BIO’s Innovator in Biotechnology award recognizes Members of Congress who have been collaborative partners, advocates, and champions of the biotechnology and life sciences industries. 

“The life sciences industry in Georgia provides jobs for over 32,000 people. Congressman Collins has been an invaluable advocate for the biotechnology community – both in Georgia’s 9th District and the nation at large,” said Maria Thacker Goethe, President & CEO, Georgia Bio.  “On behalf of the Georgia life science industry, we thank him for outstanding leadership and dedication to supporting the innovative capacity and job-creating potential of American life science companies.”

<< first < Prev 1 2 3 4 5 6 7 8 9 10 Next > last >>

Page 7 of 49